The carrying values of the Company's outstanding debt obligations as of September 30, 2025, and December 31, 2024, were as follows:


(U.S. Dollars, in thousands)	September 30, 2025			December 31, 2024
	(Unaudited)
Outstanding Term Loans
Principal amount	$	160,000		$	160,000
Unamortized original debt discount		(1,961	)		(2,327	)
Unamortized debt issuance costs and lenders fees		(820	)		(658	)
Total indebtedness from outstanding term loans	$	157,219		$	157,015

Revolving Credit Facilities
Principal amount outstanding	$	—		$	—
Total indebtedness outstanding	$	157,219		$	157,015

Current portion of long-term debt	$	—		$	—
Long-term debt		157,219			157,015
Total indebtedness outstanding	$	157,219		$	157,015

On November 7, 2024, the Company, as borrower, and its U.S. subsidiaries entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. The Credit Agreement contains financial covenants requiring the Company to maintain (i) a minimum level of liquidity at all times and (ii) a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. [As of September 30, 2025, the Company was in compliance with all required financial covenants.]

As of September 30, 2025, the Company had no borrowings on its available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.5 million).